Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
Status:
RECRUITING
Trial end date:
2034-03-01
Target enrollment:
Participant gender:
Summary
This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.